article_metadata: Shiyu Mao Junfeng Zhang Yadong Guo Ziwei Zhang Yuan Wu Wentao Zhang Longsheng Wang Jiang Geng Yang Yan Xudong Yao
article_metadata: 10.2147/DDDT.S181122
article_metadata: Drug Des Devel Ther
article_metadata: 2019 Jan 11;13:291-300.
article_metadata: mdm2 hyperprogression immune checkpoint blockade programmed cell death ligand-1 urothelial bladder carcinoma
article_metadata: CC BY-NC
article_metadata: https://pubmed.ncbi.nlm.nih.gov/30666091/
article_metadata: Antineoplastic Agents / therapeutic use B7-H1 Antigen / metabolism Cisplatin / therapeutic use Urinary Bladder Neoplasms / therapy
article_metadata: Antineoplastic Agents / therapeutic use B7-H1 Antigen / metabolism Cisplatin / therapeutic use Urinary Bladder Neoplasms / therapy Case Reports Administration, Intravesical Antineoplastic Agents / administration & dosage Cisplatin / administration & dosage Humans Immunotherapy Male Middle Aged Urinary Bladder Neoplasms / metabolism Urinary Bladder Neoplasms / secondary Antineoplastic Agents B7-H1 Antigen Cisplatin
article_metadata: PMC6333318
article_metadata: 30666091
article_metadata: Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report
article_metadata: 2019